Orchid Cellmark's Q4, FY '08 Revenues Drop | GenomeWeb

NEW YORK (GenomeWeb News) – Orchid Cellmark today reported that its fourth-quarter and fiscal 2008 revenues declined due to lower UK revenues and a decline in revenues from forensic casework and its CODIS business.

Orchid brought in total revenues of $13 million for the three-month period ended Dec. 31, a drop of 13 percent from revenues of $15 million for the fourth quarter of 2007.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.